Table 2.
COVID-19–SOT Recipient Symptoms, Lab Results, and Treatments
| Measure | All Patients | Nonsevere COVID-19 | Severe COVID-19 | P Value |
|---|---|---|---|---|
| Month of first positive COVID test, n (%) | n = 58 | n = 38 | n = 20 | |
| March | 6 (10.3) | 4 (10.5) | 2 (10) | * |
| April | 21 (36.2) | 14 (36.8) | 7 (35) | .8897 |
| May | 13 (22.4) | 7 (18.4) | 6 (30) | .3148 |
| June | 5 (8.6) | 1 (2.6) | 4 (20) | * |
| July | 10 (17.2) | 7 (18.4) | 3 (15) | .3430 |
| August | 2 (3.4) | 1 (2.6) | 1 (5) | * |
| September | 1 (1.7) | 1 (2.6) | 0 (0) | * |
| Presenting symptoms, n (%) | n = 54 | n = 35 | n = 19 | |
| Fever | 25 (46.3) | 15 (42.9) | 10 (52.6) | .4416 |
| Cough | 25 (46.3) | 9 (25.7) | 16 (84.2) | < .0001 |
| Dyspnea | 20 (37) | 9 (25.7) | 11 (57.9) | .0071 |
| Fatigue, myalgias | 11 (20.4) | 7 (20) | 4 (21) | .8841 |
| Diarrhea, vomiting | 10 (18.5) | 8 (22.9) | 2 (10.5) | .2895 |
| Pharyngitis | 5 (9.3) | 5 (14.3) | 0 (0) | * |
| Loss of taste/smell | 2 (3.7) | 2 (5.7) | 0 (0) | * |
| Labs at presentation, n (%) | n = 45 | n = 28 | n = 17 | |
| WBC <4 (4.0-10.8 × 103/mL) | 15 (33.3) | 13 (46.4) | 2 (11.8) | .0453 |
| Platelets <150 (130-400 × 103/mL) | 19 (42.2) | 8 (28.6) | 11 (64.7) | .0088 |
| AST >40 (18-54 U/L) | 10 (22.2) | 5 (17.9) | 5 (29.4) | .2564 |
| ALT >40 (10-50 U/L) | 7 (15.6) | 2 (7) | 5 (29.4) | * |
| CRP >10 (<5.0 mg/L) | n = 34 | n = 21 | n = 13 | |
| 16 (47) | 5 (23.8) | 11 (84.6) | .0007 | |
| Diagnosis of pneumonia | n = 57 | n = 38 | n = 19 | |
| 35 (61.4) | 16 (42) | 19 (100) | .0001 | |
| Hospitalized, n | n = 41 | n = 23 | n = 18 | |
| Length of stay, mean (SD), d | 11.1 (12.7) | 5.0 (2.7) | 19.0 (16.1) | .0003 |
| ICU admission, n (%) | 12 (29.3) | 0 (0) | 12 (66.7) | < .0001 |
| Mechanical ventilation | 10 (24.4) | 0 (0) | 10 (55.6) | < .0001 |
| ECMO | 2 (4.9) | 0 (0) | 2 (11) | * |
| Readmitted within 3 months, n (%) | 14 (34) | 9 (39) | 5 (27.8) | |
| COVID treatment, n (%) | n = 55 | n = 36 | n = 19 | |
| Hydroxychloroquine | 14 (25.5) | 10 (27.8) | 4 (21) | .5932 |
| Remdesivir | 6 (10.9) | 0 (0) | 6 (31.6) | * |
| Convalescent plasma | 7 (12.7) | 1 (2.8) | 6 (31.6) | * |
| Corticosteroids | 10 (18) | 1 (2.8) | 9 (47.4) | .0000 |
| Tocilizumab | 2 (36.3) | 0 (0) | 2 (10.5) | * |
| Adjustment in IS | 36 (65.5) | 20 (55.6) | 16 (84.2) | .0412 |
| MMF held | 27 (50) | 15 (42.9) | 12 (63) | .1363 |
| Acute kidney injury, n (%) | n = 54 | n = 35 | n = 19 | |
| 25 (46.3) | 14 (40) | 11 (58) | .1844 | |
| Mortality (inpatient + outpatient), n (%) | n = 58 | n = 38 | n = 20 | |
| 10 (17.2) | 0 (0) | 10 (50) | < .0001 |
t tests were used for age-related continuous measures. χ2 tests were used for categorical variables.
ALT, alanine aminotransferase; AST, aspartate transaminase; COVID-19, coronavirus disease 2019; CRP, C-reactive protein; ECMO, extracorporeal membrane oxygenation; ICU, intensive care unit; IS, immunosuppression; MMF, mycophenolate mofetil; SD, standard deviation; SOT, solid organ transplant; WBC, white blood cell.
⁎
Test was not performed when N < 9.